相关实验视频
Updated: Jul 20, 2025

06:00
Fixation and Operational Method for Abdominal Massage in T2DM Mice
Published on: March 7, 2025
239
鲁丁及其与甲福明的结合对1型糖尿病中血管功能的影响
Sheba R David1, Penny Pei Ni Lai2, Jestin Chellian3
1School of Pharmacy, University of Wyoming, Laramie, WY, 82071, USA. snakkada@uwyo.edu.
Scientific reports
|August 1, 2023
概括
鲁丁和甲福明的联合治疗显著改善了糖尿病大鼠的血糖,脂质水平和血管功能. 这种组合显示出管理糖尿病并发症的潜力.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 生理学 生理学 生理学
背景情况:
- 糖尿病的特点是高血糖和脂质不良.
- 糖尿病并发症包括血管功能受损和器官损伤.
- 目前的抗糖尿病治疗可能存在局限性,需要新的治疗策略.
研究的目的:
- 调查单独和组合使用的路丁和甲福明对链毒素诱导的糖尿病大鼠的代谢和血管参数的影响.
- 评估这种联合治疗对胰腺,肝脏和脏组织学的影响.
主要方法:
- 在Sprague Dawley大鼠中使用链毒素 (STZ) 诱导糖尿病.
- 鲁丁 (100毫克/公斤) 和甲胺 (300毫克/公斤) 进行口服,持续4周.
- 评估了血葡萄糖,脂质样本,大动脉环反应 (血管收缩/放松) 和器官组织学.
主要成果:
- 单一治疗中,路丁和甲福明均改善了血糖,胆固醇和甘油三水平.
- 与单一治疗相比,组合疗法在使这些代谢参数正常化方面表现出更高的疗效.
- 糖尿病大鼠表现出血管功能受损 (放松减少,收缩增加),这种情况在组合治疗中得到显著改善.
- 组织学分析显示,结合疗法显著改善了胰腺,肝脏和脏组织.
结论:
- 鲁丁和美特福林联合治疗在糖尿病大鼠的高血糖和脂质失调管理中提供了显著的好处.
- 这种组合有效地恢复了血管功能,并减轻了与糖尿病相关的器官损伤.
- 路丁和甲胺的协同作用表明,对于糖尿病及其并发症来说,这是一个有前途的治疗方法.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Dipeptidyl Peptidase 4 Inhibitors
212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
Diabetes: Management and Pharmacotherapy
313
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
313
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208
Oral Hypoglycemic Agents: Sulfonylureas
245
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
245

